Literature DB >> 6602054

The origin of human B and T cells from multipotent stem cells: a study of the Tn syndrome.

J C Brouet, W Vainchenker, D Blanchard, U Testa, J P Cartron.   

Abstract

The Tn (or polyagglutinability) syndrome corresponds to a human nonmalignant acquired condition which results from a somatic mutation occurring at the level of bone marrow stem cells. This model offers therefore a unique opportunity to study the contribution of multipotential stem cells to the maintenance of cells from the lymphoid lineage. We found that the Tn mutation is expressed by both myeloid and lymphoid mature blood cells. Whereas a large proportion of surface IgM-bearing B cells carry the Tn mutation, only a small percentage of T cells and IgA- or IgG-bearing B cells are defective, showing that under physiological conditions the penetration of stem cells into the various myeloid and lymphoid compartments is variable.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6602054     DOI: 10.1002/eji.1830130416

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  4 in total

1.  Constitutively hyposialylated human T-lymphocyte clones in the Tn-syndrome: binding characteristics of plant and animal lectins.

Authors:  K Mrkoci; S Kelm; P R Crocker; R Schauer; E G Berger
Journal:  Glycoconj J       Date:  1996-08       Impact factor: 2.916

2.  Cosmc is required for T cell persistence in the periphery.

Authors:  Christopher E Cutler; Mark B Jones; Alicia A Cutler; Amanda Mener; Connie M Arthur; Sean R Stowell; Richard D Cummings
Journal:  Glycobiology       Date:  2019-10-21       Impact factor: 4.313

3.  Presence of the Tn antigen on hematopoietic progenitors from patients with the Tn syndrome.

Authors:  W Vainchenker; G Vinci; U Testa; A Henri; A Tabilio; M P Fache; H Rochant; J P Cartron
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

4.  Blood group A cross-reacting epitope defined by monoclonal antibodies NCC-LU-35 and -81 expressed in cancer of blood group O or B individuals: its identification as Tn antigen.

Authors:  S Hirohashi; H Clausen; T Yamada; Y Shimosato; S Hakomori
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.